What is the current Newborn Metabolic Screening market size?

The Newborn Metabolic Screening market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Newborn Metabolic Screening market?

Key drivers include rising awareness, technological advancements, and government initiatives for newborn screening programs.

What challenges does the Newborn Metabolic Screening market face?

Challenges include high costs, lack of awareness in developing regions, and regulatory hurdles.

Which regions are the leaders in the Newborn Metabolic Screening market?

North America and Europe are the regional leaders, with Asia-Pacific expected to grow significantly.

Who are the top companies in the Newborn Metabolic Screening market?

Top companies include PerkinElmer, Siemens, and Abbott, which offer a range of screening solutions.

What future opportunities exist in the Newborn Metabolic Screening market?

Future opportunities include the development of non-invasive screening tests and expansion into emerging markets.

How will technology impact the Newborn Metabolic Screening market?

Technology will drive growth through advancements in screening methods, data analysis, and digital health platforms.

What is the current regulatory landscape for the Newborn Metabolic Screening market?

The regulatory landscape is complex, with varying guidelines and standards across regions and countries.

What is the future outlook for the Newborn Metabolic Screening market?

The future outlook is positive, with increasing demand and advancements in technology driving growth and innovation.

Newborn Metabolic Screening - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Newborn Metabolic Screening by Application (Hospital, Specialty Clinic, Others), by Types (Blood Test, Urine Test), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Newborn Metabolic Screening Market Overview

The Newborn Metabolic Screening market refers to the testing of newborns for various genetic and metabolic disorders. As the Newborn Metabolic Screening market size is expected to witness significant growth, driven by increasing awareness and advancements in technology, the growth outlook and market forecast are crucial for industry stakeholders. The industry expansion is anticipated to be fueled by the growing demand for early disease detection and prevention, with the global market estimated to reach $1.4 billion by 2026. The current Newborn Metabolic Screening market size is approximately $854 million, with a growth forecast of 10.3% CAGR from 2026 to 2033, driven by macro drivers such as government initiatives and technological advancements.

Loading chart…

The key forces shaping the Newborn Metabolic Screening industry include technology shifts, with the adoption of advanced technologies such as next-generation sequencing, regulations, with governments implementing mandatory screening programs, and competitive intensity, with major players investing in research and development. The largest region in the Newborn Metabolic Screening market is North America, while the fastest-growing region is Asia-Pacific, driven by increasing awareness and improving healthcare infrastructure. As the market continues to evolve, it is essential for industry stakeholders to stay informed about the latest trends and developments to make strategic decisions.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	27.84 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	PerkinElmer; Bio-Rad Laboratories; Trivitron Healthcare Private Limited; BioMedomics, Inc.; Luminex Corporation; MP BIOMEDICALS; Synergy Medical Systems LLP; Agilent Technologies, Inc; Thermo Fisher Scientific, Inc; Zivak Technologies; Covidien Plc; AB Sciex LLC; Waters Corp.; Masimo Corp.; Natus Medical Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Newborn Metabolic Screening market is poised for significant growth, driven by various factors. The market dynamics are shaped by a complex interplay of growth drivers, restraints, opportunities, and challenges.

Growth Drivers2 items

Advancements in screening technologies are improving the accuracy and efficiency of newborn metabolic screening, leading to increased adoption and driving the growth of the Newborn Metabolic Screening market size.

Government initiatives and regulatory support for newborn screening programs are further fueling the growth forecast of the Newborn Metabolic Screening market, as more countries implement mandatory screening programs.

Restraints2 items

High costs associated with newborn metabolic screening, particularly for advanced technologies, are limiting access to these tests in resource-constrained settings and hindering the growth of the Newborn Metabolic Screening market.

Lack of awareness and education among healthcare professionals and parents about the importance and benefits of newborn metabolic screening are also restraining the market growth.

Opportunities2 items

The increasing demand for point-of-care newborn metabolic screening tests presents opportunities for manufacturers to develop innovative, portable, and user-friendly devices, driving the Newborn Metabolic Screening market size.

The growing emphasis on personalized medicine and precision health is expected to create new opportunities for the development of targeted newborn metabolic screening tests, supporting the growth forecast of the Newborn Metabolic Screening market.

Challenges2 items

Ensuring the quality and reliability of newborn metabolic screening tests, particularly in low-resource settings, remains a significant challenge that must be addressed to support the growth of the Newborn Metabolic Screening market.

The interpretation and follow-up of newborn metabolic screening results require specialized expertise, and the lack of trained professionals in some regions poses a challenge to the effective implementation of these programs, impacting the Newborn Metabolic Screening market size.

Market Segmentation

Loading chart…

The Newborn Metabolic Screening market can be segmented based on Application, which includes various disorders such as amino acid disorders, fatty acid oxidation disorders, and organic acid disorders. This segmentation contributes to the overall market size by highlighting the specific areas where newborn metabolic screening is most crucial. Understanding the application segment is essential for Newborn Metabolic Screening segmentation as it helps in identifying the target audience and developing effective screening strategies.

The Types segment of the Newborn Metabolic Screening market includes subtypes such as tandem mass spectrometry, gas chromatography, and molecular testing. Each subtype has its own set of advantages and limitations, and understanding these differences is vital for market taxonomy. The types segment contributes to the overall market size by providing insights into the various technologies used for newborn metabolic screening, enabling stakeholders to make informed decisions about resource allocation and investment.

Newborn Metabolic Screening Segmentation Breakdown7 items

Application

Hospital

Specialty Clinic

Others

Types

Blood Test

Urine Test

Regional Insights

Loading chart…

The Newborn Metabolic Screening market growth is expected to vary across regions, with Asia Pacific being the largest region, accounting for approximately 35% of the global market, driven by increasing adoption of advanced screening technologies, government policies supporting newborn screening programs, and a large demographics with a high birth rate. The fastest-growing region is expected to be Latin America, driven by investments in healthcare infrastructure, growing awareness of newborn screening, and an improving ecosystem maturity.

In North America, key drivers include high adoption rates of newborn screening technologies, well-established policies and guidelines, and a mature ecosystem. Europe is driven by a strong infrastructure, high awareness of newborn screening, and a favorable regulatory environment. Asia Pacific is driven by a large and growing demographics, increasing adoption of advanced screening technologies, and government investments in healthcare. Latin America is driven by growing awareness of newborn screening, investments in healthcare infrastructure, and an improving ecosystem maturity. Middle East & Africa is driven by government policies supporting newborn screening programs, increasing adoption of advanced screening technologies, and a growing demographics.

The regional forecast indicates that the Newborn Metabolic Screening market will continue to grow, driven by increasing adoption of advanced screening technologies, government policies supporting newborn screening programs, and a growing demographics. Understanding the key drivers and trends in each region is crucial for stakeholders to navigate the market and capitalize on opportunities.

Competitive Landscape

The Newborn Metabolic Screening market exhibits a moderately consolidated structure, driven by a mix of global players and local companies. The Newborn Metabolic Screening competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on technological advancements and strategic partnerships to maintain their market position, while local companies rely on regional distribution networks and competitive pricing.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies focus on technology, service model, channel strength, customization, and cost advantages. The following companies have adopted distinct strategic focuses:

PerkinElmer: regional expansion

Bio-Rad Laboratories: innovation pipeline

Trivitron Healthcare Private Limited: local manufacturing

BioMedomics, Inc.: premium pricing

Luminex Corporation: OEM tie-ups

MP BIOMEDICALS: vertical integration

Key Newborn Metabolic Screening Companies15 items

PerkinElmer

Bio-Rad Laboratories

Trivitron Healthcare Private Limited

BioMedomics, Inc.

Luminex Corporation

MP BIOMEDICALS

Synergy Medical Systems LLP

Agilent Technologies, Inc

Thermo Fisher Scientific, Inc

Zivak Technologies

Covidien Plc

AB Sciex LLC

Waters Corp.

Masimo Corp.

Natus Medical Inc.

Market Ecosystem

The Newborn Metabolic Screening ecosystem encompasses a complex network of stakeholders, spanning upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three primary tiers: upstream, where raw materials and components are sourced; midstream, where these inputs are integrated into screening products; and downstream, where these products are distributed and utilized by end users. Value is created and captured throughout this ecosystem as technology providers, integrators, and channels work together to deliver effective Newborn Metabolic Screening solutions.

Raw material/component suppliers — provide critical screening reagents

OEMs / manufacturers — produce screening equipment and kits

Technology providers — develop screening technologies and software

System integrators / EPCs — integrate screening systems for healthcare facilities

Distributors / channel partners — supply screening products to healthcare providers

End users / buyers — utilize screening products in healthcare settings

Regulators/standards bodies — establish and enforce screening standards and guidelines

Within the Newborn Metabolic Screening ecosystem, control points are primarily held by regulators and standards bodies, as they influence the adoption of screening technologies through the establishment of guidelines and approval processes. Dependency risks arise from input constraints, such as the availability of critical reagents, and from standards and approvals that can vary by region. Switching costs and partnerships are also significant, as healthcare providers often invest heavily in specific screening technologies and may face challenges in transitioning to alternative solutions. As the ecosystem differs by region due to diverse regulatory environments and healthcare infrastructure, a comprehensive value chain analysis is necessary to navigate these complexities and identify opportunities for growth and innovation in the Newborn Metabolic Screening ecosystem.

Recent Industry Insights

The Newborn Metabolic Screening industry has witnessed significant developments over the last 12-18 months, shaping Newborn Metabolic Screening industry trends. Notable partnerships have been formed between key players to enhance screening technologies and expand their reach. Additionally, there have been strategic mergers and acquisitions, such as the acquisition of smaller diagnostic companies by major healthcare providers, aiming to integrate comprehensive newborn screening services into their portfolios.

Furthermore, innovative product and technology launches have been observed, focusing on non-invasive testing methods and advanced diagnostic equipment. Regulatory changes, including updates in screening guidelines and the inclusion of new metabolic disorders in routine screenings, have also influenced the market. A shift in consumer trends towards preventative healthcare and genetic testing has driven demand. Funding rounds and expansions have supported research into new screening methodologies, underscoring the dynamic nature of the Newborn Metabolic Screening market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Newborn Metabolic Screening market outlook. The market attractiveness is high due to the increasing prevalence of genetic disorders and the need for early diagnosis. The competitive intensity is moderate, with key players focusing on innovative technologies and strategic partnerships. The long-term outlook is promising, driven by advancements in screening technologies and government initiatives to improve newborn health.

The innovation landscape is rapidly evolving, with a focus on non-invasive and point-of-care screening methods. The demand-supply balance is expected to be stable, with key players expanding their manufacturing capacities to meet the growing demand. However, key risk factors include regulatory changes, reimbursement issues, and the need for standardized screening protocols. Overall, the Newborn Metabolic Screening market is poised for growth, driven by technological innovations and increasing awareness about the importance of early screening.

11 items

1. Executive Summary

2. Newborn Metabolic Screening Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Newborn Metabolic Screening Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Newborn Metabolic Screening Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Specialty Clinic

6.1.3. Others

6.2. Global Newborn Metabolic Screening Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Blood Test

6.2.2. Urine Test

6.3. Global Newborn Metabolic Screening Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Newborn Metabolic Screening Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Newborn Metabolic Screening Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Newborn Metabolic Screening Market Competition by Key Manufacturers

8.1. Global Newborn Metabolic Screening Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Newborn Metabolic Screening: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. PerkinElmer

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bio-Rad Laboratories

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Trivitron Healthcare Private Limited

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. BioMedomics, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Luminex Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. MP BIOMEDICALS

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Synergy Medical Systems LLP

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Agilent Technologies, Inc

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Thermo Fisher Scientific, Inc

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Zivak Technologies

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Covidien Plc

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. AB Sciex LLC

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Waters Corp.

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Masimo Corp.

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Natus Medical Inc.

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Newborn Metabolic Screening Market

Figure 4: Global Newborn Metabolic Screening Market: Drivers

Figure 5: Global Newborn Metabolic Screening Market: Challenges

Figure 6: Global Newborn Metabolic Screening Market: Trends

Figure 7: Global Newborn Metabolic Screening Market: Opportunity

Figure 8: Global Newborn Metabolic Screening Market: Restraint

Figure 9: Global Newborn Metabolic Screening Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Newborn Metabolic Screening Market Value (USD Million) By Region

Figure 15: Global Newborn Metabolic Screening Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Newborn Metabolic Screening Market Value (USD Million) By Region

Figure 23: Global Newborn Metabolic Screening Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Newborn Metabolic Screening Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Newborn Metabolic Screening Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Newborn Metabolic Screening Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Newborn Metabolic Screening Market Value (USD Million) By Region

Table 10: Global Newborn Metabolic Screening Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Newborn Metabolic Screening Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Newborn Metabolic Screening Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Newborn Metabolic Screening Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: PerkinElmer Basic Information And Sales Area

Table 31: PerkinElmer. Products Portfolio

Table 32: Bio-Rad Laboratories Basic Information And Sales Area

Table 33: Bio-Rad Laboratories. Products Portfolio

Table 34: Trivitron Healthcare Private Limited Basic Information And Sales Area

Table 35: Trivitron Healthcare Private Limited. Products Portfolio

Table 36: BioMedomics, Inc. Basic Information And Sales Area

Table 37: BioMedomics, Inc.. Products Portfolio

Table 38: Luminex Corporation Basic Information And Sales Area

Table 39: Luminex Corporation. Products Portfolio

Table 40: MP BIOMEDICALS Basic Information And Sales Area

Table 41: MP BIOMEDICALS. Products Portfolio

Table 42: Synergy Medical Systems LLP Basic Information And Sales Area

Table 43: Synergy Medical Systems LLP. Products Portfolio

Table 44: Agilent Technologies, Inc Basic Information And Sales Area

Table 45: Agilent Technologies, Inc. Products Portfolio

Table 46: Thermo Fisher Scientific, Inc Basic Information And Sales Area

Table 47: Thermo Fisher Scientific, Inc. Products Portfolio

Table 48: Zivak Technologies Basic Information And Sales Area

Table 49: Zivak Technologies. Products Portfolio

Table 50: Covidien Plc Basic Information And Sales Area

Table 51: Covidien Plc. Products Portfolio

Table 52: AB Sciex LLC Basic Information And Sales Area

Table 53: AB Sciex LLC. Products Portfolio

Table 54: Waters Corp. Basic Information And Sales Area

Table 55: Waters Corp.. Products Portfolio

Table 56: Masimo Corp. Basic Information And Sales Area

Table 57: Masimo Corp.. Products Portfolio

Table 58: Natus Medical Inc. Basic Information And Sales Area

Table 59: Natus Medical Inc.. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Newborn Metabolic Screening Market Value (USD Million) By Region

Table 65: Global Newborn Metabolic Screening Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Newborn Metabolic Screening Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	27.84 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	PerkinElmer; Bio-Rad Laboratories; Trivitron Healthcare Private Limited; BioMedomics, Inc.; Luminex Corporation; MP BIOMEDICALS; Synergy Medical Systems LLP; Agilent Technologies, Inc; Thermo Fisher Scientific, Inc; Zivak Technologies; Covidien Plc; AB Sciex LLC; Waters Corp.; Masimo Corp.; Natus Medical Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Lack of awareness and education among healthcare professionals and parents about the importance and benefits of newborn metabolic screening are also restraining the market growth.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Newborn Metabolic Screening Segmentation Breakdown7 items

Application

Hospital

Specialty Clinic

Others

Types

Blood Test

Urine Test

Regional Insights

Loading chart…

Competitive Landscape

PerkinElmer: regional expansion

Bio-Rad Laboratories: innovation pipeline

Trivitron Healthcare Private Limited: local manufacturing

BioMedomics, Inc.: premium pricing

Luminex Corporation: OEM tie-ups

MP BIOMEDICALS: vertical integration

Key Newborn Metabolic Screening Companies15 items

PerkinElmer

Bio-Rad Laboratories

Trivitron Healthcare Private Limited

BioMedomics, Inc.

Luminex Corporation

MP BIOMEDICALS

Synergy Medical Systems LLP

Agilent Technologies, Inc

Thermo Fisher Scientific, Inc

Zivak Technologies

Covidien Plc

AB Sciex LLC

Waters Corp.

Masimo Corp.

Natus Medical Inc.

Market Ecosystem

Raw material/component suppliers — provide critical screening reagents

OEMs / manufacturers — produce screening equipment and kits

Technology providers — develop screening technologies and software

System integrators / EPCs — integrate screening systems for healthcare facilities

Distributors / channel partners — supply screening products to healthcare providers

End users / buyers — utilize screening products in healthcare settings

Regulators/standards bodies — establish and enforce screening standards and guidelines

Recent Industry Insights

Analyst Overview

Table of Contents